Form 4/A for BBNX Beta Bionics, Inc.
Accepted 2026-07-02 18:44:29 ET · period of report 2026-06-26 · accession 0002048588-26-000010 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMAT | 2026-07-02 18:44 | 2026-06-26+ | BBNX | Feider Stephen | CFO | M - OptEx | $5.10 | +10.0K | 170.9K | +6% | +$51.0K |
| DMAT | 2026-07-02 18:44 | 2026-06-26+ | BBNX | Feider Stephen | CFO | S - Sale+OE | $17.04 | -10.0K | 166.1K | -6% | -$170.4K |
| DMAT | 2026-07-02 18:44 | 2026-06-26+ | BBNX | Feider Stephen | CFO | M - OptEx | $0.00 | -10.0K | 39.7K | -20% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-26 | M | A | 5,104 | $5.10 | 171,157 | D | — | — | (F1) This Form 4 is being amended to correct the number of shares subject to the option exercise that occurred on June 26, 2026, in connection with the reported sales and to correct the number of securities beneficially owned following the reported transactions. (F1) This Form 4 is being amended to correct the number of shares subject to the option exercise that occurred on June 26, 2026, in connection with the reported sales and to correct the number of securities beneficially owned following the reported transactions. |
| 2 | Common | Common Stock | 2026-06-26 | S | D | 5,104 | $17.05 | 166,053 | D | — | — | (F2) Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on May 15, 2025. (F3) The weighted average sale price for the transaction reported was $17.046782 and the range of prices were between $17 and $17.12. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. (F1) This Form 4 is being amended to correct the number of shares subject to the option exercise that occurred on June 26, 2026, in connection with the reported sales and to correct the number of securities beneficially owned following the reported transactions. |
| 3 | Common | Common Stock | 2026-06-29 | M | A | 4,896 | $5.10 | 170,949 | D | — | — | (F1) This Form 4 is being amended to correct the number of shares subject to the option exercise that occurred on June 26, 2026, in connection with the reported sales and to correct the number of securities beneficially owned following the reported transactions. |
| 4 | Common | Common Stock | 2026-06-29 | S | D | 4,896 | $17.03 | 166,053 | D | — | — | (F2) Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on May 15, 2025. (F4) The weighted average sale price for the transaction reported was $17.0304 and the range of prices were between $17 and $17.08. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. (F1) This Form 4 is being amended to correct the number of shares subject to the option exercise that occurred on June 26, 2026, in connection with the reported sales and to correct the number of securities beneficially owned following the reported transactions. |
| 5 | Derivative | Employee Stock Option (right to buy) | 2026-06-26 | M | D | 5,104 | $0.00 | 44,591 | D | $5.10 · — to 2033-09-13 | 5,104 Common Stock | (F1) This Form 4 is being amended to correct the number of shares subject to the option exercise that occurred on June 26, 2026, in connection with the reported sales and to correct the number of securities beneficially owned following the reported transactions. (F5) The shares subject to this option shall vest in 48 equal monthly installments measured from September 14, 2023. (F1) This Form 4 is being amended to correct the number of shares subject to the option exercise that occurred on June 26, 2026, in connection with the reported sales and to correct the number of securities beneficially owned following the reported transactions. (F1) This Form 4 is being amended to correct the number of shares subject to the option exercise that occurred on June 26, 2026, in connection with the reported sales and to correct the number of securities beneficially owned following the reported transactions. |
| 6 | Derivative | Employee Stock Option (right to buy) | 2026-06-29 | M | D | 4,896 | $0.00 | 39,695 | D | $5.10 · — to 2033-09-13 | 4,896 Common Stock | (F5) The shares subject to this option shall vest in 48 equal monthly installments measured from September 14, 2023. (F1) This Form 4 is being amended to correct the number of shares subject to the option exercise that occurred on June 26, 2026, in connection with the reported sales and to correct the number of securities beneficially owned following the reported transactions. |